{"product_id":"challenging-cases-in-immunotherapy-related-organ-toxicities","title":"Challenging Cases in Immunotherapy Related Organ Toxicities","description":"\u003cdiv class=\"expanded\" id=\"bookDescriptionBox\"\u003e\n\u003cdiv data-expanded=\"true\" class=\"a-expander-content a-expander-partial-collapse-content a-expander-content-expanded\"\u003e\n\u003cdiv id=\"bookDescription_feature_div\" class=\"celwidget\" data-feature-name=\"bookDescription\" data-csa-c-type=\"widget\" data-csa-c-content-id=\"bookDescription\" data-csa-c-slot-id=\"bookDescription_feature_div\" data-csa-c-asin=\"3031935454\" data-csa-c-is-in-initial-active-row=\"false\" data-csa-c-id=\"vpymeo-ebe2w1-8laqbk-7clbow\" data-cel-widget=\"bookDescription_feature_div\"\u003e\n\u003cdiv data-a-expander-name=\"book_description_expander\" data-a-expander-collapsed-height=\"280\" class=\"a-expander-collapsed-height a-row a-expander-container a-spacing-base a-expander-partial-collapse-container\"\u003e\n\u003cdiv data-expanded=\"false\" class=\"a-expander-content a-expander-partial-collapse-content\"\u003e\n\u003cp\u003e\u003cspan\u003eWith the widespread adoption of checkpoint inhibitors as standard-of-care therapy for many cancers, the associated toxicities affecting multiple organ systems have become a significant limiting factor, particularly in select patient populations. Some organ-specific toxicities can be severe and life-threatening. Early recognition and prompt, effective management of these conditions are critical to improving patient care and ensuring the continued delivery of cancer therapy over the long term.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDesigned as a companion volume to our first handbook \u003c\/span\u003e\u003cspan class=\"a-text-italic\"\u003eManaging Immunotherapy-Related Organ Toxicities\u003cspan\u003e \u003c\/span\u003e\u003c\/span\u003e\u003cspan\u003epublished in 2022, this new book presents 65 unique and challenging cases involving toxicities across more than ten different organ systems. Each case includes a detailed clinical presentation, evaluation, treatment approach, and long-term patient outcome. The contributors are a group of leading experts from 14 centers worldwide, all of whom provide routine care for patients with complex toxicity conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eThis is the first book of its kind, \u003c\/span\u003e\u003cspan class=\"a-text-italic\"\u003eChallenging Cases of Immunotherapy-Related Organ Toxicities,\u003cspan\u003e \u003c\/span\u003e\u003c\/span\u003e\u003cspan\u003ehighlighting the real-world challenges physicians encounter in oncology clinical practice.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c!--StartFragment --\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eTable of contents (56 chapters)\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eFront Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages i-xiv\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eCardiology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eFront Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 1-1\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eDownload chapter PDF \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eComplete Heart Block and Myocarditis Related to Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eNoah Beinart, Nicolas L. Palaskas\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 3-8\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eDermatology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eFront Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 9-9\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eDownload chapter PDF \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eBullous Pemphigoid Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eHannah Y. Wang, Phyu Aung, Anisha B. Patel\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 11-20\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eErosive Oral Lichen Planus with Pemphigus Vulgaris Post Immune Checkpoint Inhibitor Treatment\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eHannah Y. Wang, Carlos A. Torres-Cabala, Anisha B. Patel\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 21-32\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eDermatomyositis Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eRishabh Lohray, Anisha B. Patel\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 33-42\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eRapid Resolution of Refractory Immunotherapy-Related Transient Acantholytic Dermatosis with Dupilumab\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eMelissa R. Laughter, Ata S. Moshiri\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 43-47\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eEndocrinology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eFront Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 49-49\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eDownload chapter PDF \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eHypophysitis Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eSean Ngo, Jeena Varghese\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 51-56\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eGraves’ Disease After Prolonged Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eJanki Patel, Conor Best\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 57-61\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eWorsening Hyperglycemia During Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eIrene J. Lee, Kei Takigawa, Conor Best\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 63-67\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eLipodystrophy after Receiving Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eNina Semsarzadeh, Pradnya D. Patil, Kord Honda, Joshua Arbesman, Pauline Funchain\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 69-74\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eHypoglycemia Secondary to Anti-PD-1 Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eSkyler Burke, Evan Ong, Adam Bograd, Laura Bovee, Kelly G. Paulson\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 75-79\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eTransient Diabetes Insipidus Related to Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eAnna Olsson-Brown\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 81-86\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eGastroenterology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eFront Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 87-87\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eDownload chapter PDF \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eAppendicitis Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eAntony Mathew, Yang Lu, Malek Shatila, Nizar M. Tannir, Bilal Siddiqui, Yinghong Wang\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 89-94\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eCholecystitis Related to Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eMalek Shatila, Krishnavathana Varatharajalu, Gottumukkala Subba Raju, Anusha S. Thomas, Yinghong Wang\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 95-101\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eColitis Following Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eMalek Shatila, Krishnavathana Varatharajalu, Herbert Dupont, Robert Jenq, Franck Carbonnel, Stephen Hanauer et al.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 103-111\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eCMV Colitis with Perforation Post Immune Checkpoint Inhibitor Therapy with Multi-Organ Failure\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eNitish Mittal, Christine Catinis, Yang Lu, Swaminathan Padmanabhan Iyer, Pablo C. Okhuysen, Yinghong Wang\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 113-118\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e\u003c!--EndFragment --\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c!--StartFragment --\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eGastroenterology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eDiverticulitis Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eAustin R. Thomas, Yang Lu, Karen Amelia Nahmod, Dongfeng Tan, Mehmet Altan, Mehnaz A. Shafi et al.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 119-124\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eEnteritis and Venous Thromboembolism Related to Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eSidra Naz, Yang Lu, Anusha S. Thomas, Yinghong Wang\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 125-129\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eStomach Perforation Post Immune Checkpoint Inhibitors Treatment\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eAntonio Pizuorno Machado, Yang Lu, Yinghong Wang\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 131-134\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eSclerosing Mesenteritis After Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eAndrew G. Kuang, Yang Lu, Dongfeng Tan, Malek Shatila, John A. Thompson, Yinghong Wang\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 135-141\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePneumatosis Intestinalis Following Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eGabriel Sperling, Yang Lu, Malek Shatila, Krishnavathana Varatharajalu, Bryan Schneider, Anam Khan et al.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 143-148\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePouchitis Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eGabriel Sperling, Malek Shatila, Dan Zhao, Yan Zhou, Yinghong Wang\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 149-157\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eRectal Ulcer and Perianal Fistula in a Cancer Patient on Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eChristine Catinis, Nitish Mittal, Maya Sarihan, Abdullah Aleem, Jianbo Wang, Matthew T. Campbell et al.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 159-165\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eRecurrent Clostridioides Difficile Infection and Colitis Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eElliot Baerman, Kristin Junek, Rey Cerbas Lavilla, Xin Shelley Wang, Yinghong Wang\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 167-172\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eImmune Related Toxicities in Multiple Organs in a Patient with Preexisting Autoimmune Disease\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eAlice Saji, Omar Alhalabi, Shailender Bhatia, Yinghong Wang\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 173-177\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eUpper Gastrointestinal Toxicity Following Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eMalek Shatila, Krishnavathana Varatharajalu, Mehnaz A. Shafi, Anusha S. Thomas, Yinghong Wang\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 179-185\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eImmune Checkpoint Inhibitor Use in Patients with Pre-Existing Inflammatory Bowel Disease\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eDavid M. Faleck, Amitabh Srivastava, Juliana Eng\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 187-195\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eGastroparesis and Gastrointestinal Motility Dysfunction Following Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eMatthew J. Townsend, Shilpa Grover\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 197-203\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eCeliac Disease in the Setting of Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eAyo Falade, Yousef Badran, Michael Dougan\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 205-209\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eNon-Celiac Enteropathy Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eJessica El Halabi, Jessica Philpott\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 211-215\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eRefractory Immune Checkpoint Inhibitor (ICI)-Mediated Colitis\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eJoseph Sleiman, Rhonda M. Brand, Reetesh Pai, Randall E. Brand, John Rhee, Marc Schwartz et al.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 217-224\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eHematology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eFront Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 225-225\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eDownload chapter PDF \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eAutoimmune Hemolytic Anemia Post Immune Checkpoint Inhibitors\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eBlessie Elizabeth Nelson, Thein Hlaing Oo, Cristhiam Rojas-Hernandez\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 227-234\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eImmune Thrombocytopenic Purpura Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eThein Hlaing Oo, Francisco Vega, Cristhiam Rojas-Hernandez\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 235-239\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eHepatology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eFront Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 241-241\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eHepatobiliary Toxicity Secondary to Immune Checkpoint Inhibitor Therapy: Early Tocilizumab Treatment to Decouple Steroid Dependency\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eHao Chi Zhang, Sean Ngo, Deyali Chatterjee, Ethan Miller, Amado J. Zurita, Lan Wang\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 243-255\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003c!--EndFragment --\u003e\u003c\/p\u003e\n\u003cp\u003e\u003c!--StartFragment --\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eHepatology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eCholangiohepatitis with Extrahepatic Cholangiopathy and Cholecystitis Secondary to Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eHao Chi Zhang, Andres Urias Rivera, Ethan Miller, Yun Shin Chun, Celia Robinson Ledet, Lan Wang\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 257-265\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eImmune Checkpoint Inhibitor-Mediated Hepatotoxicity: Personalized Management Based on Evolving Biochemical Behaviors\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eHao Chi Zhang, Jay Shah, Asif Rashid, Ethan Miller, Pavlos Msaouel, Lan Wang\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 267-276\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eUse of Immune Checkpoint Inhibitors Prior to and After Liver Transplantation\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eAlexander Philipp, Daniel Rössler, Helga Török, Christian Lange, Enrico De Toni\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 277-283\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eNephrology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eFront Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 285-285\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eDownload chapter PDF \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eAcute Tubulointerstitial Nephritis Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eAla Abudayyeh, Jean Tayar, Amanda Tchakarov\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 287-292\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eVasculitis Post Immune Checkpoint Inhibitors Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eSehrish Qureshi, Naszrin Arani, Maria Suarez-Almazor, Amanda Tchakarov, Mehmet Altan, Ala Abudayyeh\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 293-299\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eMembranous Nephropathy Post Immune Checkpoint Inhibitors\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eAla Abudayyeh, Adi Diab, Amanda Tchakarov\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 301-305\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eNeurology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eFront Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 307-307\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eDownload chapter PDF \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eEncephalitis\/Meningoencephalitis Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eSudhakar Tummala\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 309-318\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eNeuromuscular Complications Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eSudhakar Tummala\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 319-328\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eHyperosmia Secondary to Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eJane M. Taylor, Marcus S. Dempster, Jung-Min Song, Lucy Boyce Kennedy, Pauline Funchain\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 329-334\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eOphthalmology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eFront Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 335-335\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eDownload chapter PDF \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eOptic Neuritis Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eMay Ameri, Andrew Whyte, Nagham Al-Zubidi\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 337-344\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eUveitis Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eZachary DeZeeuw, Azadeh Razmandi, Nagham Al-Zubidi\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 345-353\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eAutoimmune Retinopathy Secondary to Nivolumab\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePhillip Saikaly, Charles Drescher, Sharel C. Ongchin, Kelly G. Paulson\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 355-358\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePancreatology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eFront Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 359-359\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePancreatitis Related to Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eSidra Naz, Sireesha Yedururi, Yinghong Wang, Suresh Chari, Anusha S. Thomas\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 361-367\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eNecrotizing Pancreatitis Related to Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eSidra Naz, Sireesha Yedururi, Yinghong Wang, Suresh Chari, Anusha S. Thomas\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 369-374\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePulmonology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eFront Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 375-375\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eImmune Checkpoint Inhibitor Therapy Induced Relapsing Pneumonitis\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003eSaad Farooq, Saadia A. Faiz, Vickie R. Shannon, Ajay Sheshadri\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf1\"\u003ePages 377-385\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003c!--EndFragment --\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c!--StartFragment --\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003ePulmonology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003ePneumonitis and COVID-19 Pneumonia Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eSaad Farooq, Saadia A. Faiz, Vickie R. Shannon, Ajay Sheshadri\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003ePages 387-396\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eImmune Checkpoint Inhibitor Associated Pneumonitis in a Patient with Interstitial Lung Abnormalities\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eSaad Farooq, Saadia A. Faiz, Vickie R. Shannon, Ajay Sheshadri\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003ePages 397-405\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eTracheobronchitis Related to Pembrolizumab Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eShaun Pienkos, Gerald Berry, Kaissa de Boer, Nathaniel Myall\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003ePages 407-414\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eRheumatology\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eFront Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003ePages 415-415\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eDownload chapter PDF \u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eInflammatory Arthritis Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eSavannah Bowman, Rodabe N. Amaria, Huifang Lu\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003ePages 417-423\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eSicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eYuanteng Jeff Li, Sang T. Kim, Nizar M. Tannir, Huifang Lu\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003ePages 425-431\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003ePolymyalgia Rheumatica-Like Syndrome Post Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eHuifang Lu, Savannah Bowman, N. P. Linda Bobby, Sang T. Kim, Pavlos Msaouel, Jean Tayar\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003ePages 433-438\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eLarge Vessel Vasculitis Occurring After Exposure to Immune Checkpoint Inhibitor Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eJoshua O. Hendin, P. Scott Pollock, Pratyusha D. Banik, Scott C. DeRoo, Patricia J. Papadopoulos, Kelly D. Smith et al.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003ePages 439-445\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eMulti-organ Toxicity\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eFront Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003ePages 447-447\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eA Case of Persistent, Delayed Multisystem Toxicities After Anti-PD-1 Therapy\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eRachel S. Goodman, Hannah Burnette, Douglas B. Johnson\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003ePages 449-454\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003eBack Matter\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"pf0\"\u003e\u003cspan class=\"cf0\"\u003ePages 455-460\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003c!--EndFragment --\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv id=\"tellAmazon_feature_div\" class=\"celwidget\" data-feature-name=\"tellAmazon\" data-csa-c-type=\"widget\" data-csa-c-content-id=\"tellAmazon\" data-csa-c-slot-id=\"tellAmazon_feature_div\" data-csa-c-asin=\"3031935454\" data-csa-c-is-in-initial-active-row=\"false\" data-csa-c-id=\"hyweoa-24wyny-l64fzf-4ubfik\" data-cel-widget=\"tellAmazon_feature_div\"\u003e\n\u003cdiv class=\"celwidget c-f\" data-csa-op-log-render=\"\" data-csa-c-content-id=\"DsUnknown\" data-csa-c-slot-id=\"DsUnknown-5\" data-csa-c-type=\"widget\" data-csa-c-painter=\"tell-amazon-desktop-cards\" data-csa-c-id=\"7qq1lb-qt35cj-ytqepd-8fb952\" data-cel-widget=\"tell-amazon-desktop_DetailPage_4\"\u003e\n\u003cdiv id=\"CardInstanceu43luEQD0PPqlFpDOrOeLA\" data-card-metrics-id=\"tell-amazon-desktop_DetailPage_4\" data-acp-tracking=\"{}\" data-mix-claimed=\"true\"\u003e\n\u003cdiv data-asin=\"3031935454\" data-marketplace=\"ATVPDKIKX0DER\" data-logged-in=\"false\" class=\"_tell-amazon-desktop_style_tell_amazon_div__1YDZk\"\u003e\u003c!--EndFragment --\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003e\u003c!--EndFragment --\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"My Store","offers":[{"title":"PDF","offer_id":56778137829707,"sku":null,"price":29.99,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1031\/1204\/8971\/files\/514iAdC0nrL._SL1246.jpg?v=1773316691","url":"https:\/\/bookread.io\/products\/challenging-cases-in-immunotherapy-related-organ-toxicities","provider":"bookread","version":"1.0","type":"link"}